Daiichi Sankyo To Buy U3 Pharma Of Germany For $233.5 Million
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo says it plans to buy U3 Pharma of Germany for $233.5 million. The German bioventure specializes in antibodies as treatments for cancer. Daiichi's investment is seen as an effort to become a larger player in an area with a potential for high growth. The Japanese firm plans clinical trials of U3 Pharma drugs in Japan, the United States and Europe, drawing on the German company's ties with U.S. biotech Amgen. (Click here for more - a subscription may be required